Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07082-x
Abstract: While low density lipoprotein cholesterol (LDL-C) remains a key contributor of atherosclerotic cardiovascular disease (ASCVD), additional risk factors identified through epidemiological and genetic studies have ushered in a fertile era of drug discovery in lipid-lowering… read more here.
Keywords: risk; biotechnological drugs; risk factors; clinical trials ... See more keywords